Cost-Effectiveness of Ceftriaxone and Levofloxacin Use in Pneumonia Patients at Army Hospital Indonesia
Abstract
Pneumonia is a common respiratory tract infection worldwide and a serious issue in Indonesia, especially in Jakarta. Given the significant burden of pneumonia in Jakarta, periodic pharmacoeconomic evaluations of inpatient treatment are essential to support evidence-based policymaking. This study aims to compare the cost-effectiveness of levofloxacin and ceftriaxone, commonly used for pneumonia treatment. This study is an observational analysis using a cross-sectional method on 58 samples selected by a purposive sampling technique. The results indicate that levofloxacin provides more leukocyte reduction than ceftriaxone, and there were significant differences (p = 0.033). Although ceftriaxone therapy has a lower average direct medical cost than levofloxacin, there is no significant difference in the average direct medical cost of both therapies (p = 0.944). However, levofloxacin therapy has a lower Average Cost-Effectiveness Ratio (ACER) value of IDR 1,410.58 compared to ceftriaxone, making it more cost-effective. Switching from ceftriaxone to levofloxacin requires an additional IDR 64.00 to reduce 1 μL of leukocyte cells. Therefore, levofloxacin is concluded to be more cost-effective for treating pneumonia patients in inpatient care at Gatot Soebroto Army Hospital, Indonesia.
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause.
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.